Morgan Stanley Maintains Overweight on Akoya Biosciences, Lowers Price Target to $4
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley analyst Tejas Savant maintains an Overweight rating on Akoya Biosciences (NASDAQ:AKYA) but lowers the price target from $8 to $4.
June 03, 2024 | 1:05 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Morgan Stanley analyst Tejas Savant maintains an Overweight rating on Akoya Biosciences but lowers the price target from $8 to $4.
The lowered price target from $8 to $4 suggests a more cautious outlook on Akoya Biosciences' future performance, which could negatively impact investor sentiment and short-term stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100